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Abstract
Background: Acceptability curves have been proposed for quantifying the probability that a
treatment under investigation in a clinical trial is cost-effective. Various definitions and estimation
methods have been proposed. Loosely speaking, all the definitions, Bayesian or otherwise, relate
to the probability that the treatment under consideration is cost-effective as a function of the value
placed on a unit of effectiveness. These definitions are, in fact, expressions of the certainty with
which the current evidence would lead us to believe that the treatment under consideration is
cost-effective, and are dependent on the amount of evidence (i.e. sample size).
Methods: An alternative for quantifying the probability that the treatment under consideration is
cost-effective, which is independent of sample size, is proposed.
Results: Non-parametric methods are given for point and interval estimation. In addition, these
methods provide a non-parametric estimator and confidence interval for the incremental cost-
effectiveness ratio. An example is provided.
Conclusions: The proposed parameter for quantifying the probability that a new therapy is cost-
effective is superior to the acceptability curve because it is not sample size dependent and because
it can be interpreted as the proportion of patients who would benefit if given the new therapy.
Non-parametric methods are used to estimate the parameter and its variance, providing the
appropriate confidence intervals and test of hypothesis.
Introduction
In reporting cost-effectiveness analyses alongside clini-
cal trials, authors [1–4] have used various definitions, es-
timation methods and interpretations for acceptability
curves. Acceptability curves provide an excellent means
of quantifying the stochastic uncertainty of the estimated
incremental cost-effectiveness ratio (ICER) in relation to
a particular value ascribed to a unit of effectiveness. It is
the certainty, expressed as a probability, that the current
evidence would lead us to believe that some new therapy
is cost-effective, insofar as the ICER is less than the value
ascribed to a unit of effectiveness. In addition, accepta-
bility curves provide an estimator for the ICER and its
confidence limits. However, acceptability curves are of-
ten interpreted and expressed as the probability that the
new therapy is cost-effective. It is argued below that this
is subject to misinterpretation, and an alternative defini-
tion for a parameter representing the probability that the
new therapy is cost-effective is introduced. Data from a
clinical trial can be used to make statistical inference
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about this parameter. Furthermore, the inference pro-
vides a non-parametric estimator for the ICER and its
confidence interval.
In a two-arm randomized control trial let eji and cji be the
respective measures of effectiveness and cost for patient
i on therapy j, where j = T (treatment), S (standard); i =
1, 2, . . .nj ; and nj is the number of patients randomized
to therapy j. Typically, eji is the patient's survival time
(perhaps quality-adjusted) from randomization to death
or to the end of the period of interest. Let
. Define  c similarly.
Let E( e) = ∆ e and E( c) = ∆ c, where E is the expecta-
tion function. Thus, the incremental cost-effectiveness
ratio (ICER) is ∆ c/∆ e, and is estimated by  c /  e. In
addition, the incremental net benefit [5–9] (INB) is ∆ eλ -
∆ c, and is estimated by  eλ  -  c, where λ  is the value
given to a unit of effectiveness. Typically the INB is ex-
pressed as a function of λ , allowing readers to provide the
value they consider most relevant.
van Hout et al. [1] define the acceptability curve as "the
probability that the [ICER] is under a certain acceptable
limit", say λ . The acceptability curve, then, is a function
of λ . If one assumes that the authors are referring to the
true ICER ratio, the definition is Bayesian. In the same
paper they define the acceptability curve in algebraic
terms as  , where f is the
joint probability density function for the random vector
( e, c)'. Here the definition is not Bayesian, since it is
the probability that, in repeated sampling, the random
variable  eλ  -  c ( i.e., the observed net benefit) is
greater than 0. In an illustration, the authors substitute
the sample estimates for the model parameters in f to
yield an empirical density function, call it  , and refer to
the acceptability curve as the probability that the ICER is
acceptable. Briggs and Fenn [2] refer to the acceptability
curve as "the probability an intervention is cost-effective
in relation to different values of" λ . For estimation they
propose using the integration of  , as above, or deter-
mining the proportion of bootstrap re-samples in which
eλ  -  c is greater than 0.
Briggs[3] provides a purely Bayesian approach by defin-
ing the acceptability curve as the probability that ∆ eλ  - ∆ c
is greater than 0. In an illustration the author interprets
the acceptability curve as "probability of cost-effective".
Assuming f is the density function for a bivariate normal
random vector, and using an uninformative prior, the ac-
ceptability curve is given by A(λ )= g(x)dx, where g is
the probability density function for a normal random
variable with mean  eλ  -  c and variance
, where   and
 are estimates of the variance of eji and cji, respective-
ly, and   is an estimate of the correlation between eji and
cji . This is exactly the same curve as determined by the
integration of  , given above, and, due to the symmetry,
is equal to 1 minus the p-value of the test of the hypothe-
sis ∆ eλ  - ∆ c  < 0. In reporting the results of a cost-effec-
tiveness analysis, Raikou et al. [4] interpret the
acceptability curve as the "probability that intervention
is cost effective".
By rewriting Pr(∆ eλ  - ∆ c  > 0) as Pr(∆ c/∆ e < λ ), assuming
∆ e > 0, the acceptability curve can be interpreted as the
posterior distribution for the ICER. Defining A(λ γ ) = γ ,
the estimate for the ICER and its (1-α /2)100% Baysian
limits are given by λ 0.5, λ α /2 and λ 1-α /2, respectively.
The interpretation that the acceptability curve is the
probability that the intervention is cost-effective is not
entirely accurate and could easily be misunderstood by
policy makers. Consider the situation in which the ob-
served INB for treatment is very small, but due to a very
large sample size the acceptability curve at the value of λ
of interest is 0.99. Attaching the label "the probability
that the intervention is cost-effective" to this quantity
could mislead policy makers into thinking that treatment
is highly beneficial compared to standard. What, in fact,
is high is our confidence that the INB, however small, is
not zero. A more accurate interpretation of the accepta-
bility curve is that it is a measure of the certainty with
which the current evidence would lead us to believe that
treatment is cost-effective, i.e., ∆ eλ  - ∆ c > 0. For a Baye-
sian, this is Pr(∆ eλ  - ∆ c) > 0, and for a frequentist, it is,
assuming symmetry, 1 minus the p-value for the test of
the hypothesis ∆ eλ  - ∆ c < 0. This is not just the traditional
confusion between statistical and clinical significance. In
significance testing as the sample size increases, the var-
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iance of the estimator decreases, but the magnitude of
the parameter being estimated stays the same. However,
as sample size increase the magnitude of the acceptabili-
ty curve for a given λ  increases.
In the next section we provide a more accurate definition
for the probability that treatment is cost-effective. The
definition contains no element of certainty, and is the
probability of the "next" patient realizing a larger net
benefit if he or she is given treatment rather than stand-
ard. Using data from a clinical trial, non-parametric
methods can be used to estimate this probability, and
uncertainty
Methods
The probability that treatment is cost-effective
Let bji(λ ) = ejiλ  - cji. The quantity bji(λ ) is the net benefit,
expressed in money, realized by patient i on therapy j. An
alternative to the acceptability curve for quantifying the
probability that treatment is cost-effective is defined as:
θ (λ ) ≡  the probability, for a given λ , that a patient will re-
ceive a larger net benefit with treatment rather than
standard. Its definition is not Bayesian because it is a
probability statement about random variables, not pop-
ulation parameters. Nonetheless, it relates directly to the
notion of the probability of treatment being cost-effec-
tive. A policy maker can genuinely interpret θ (λ ) as the
probability of the "next" patient realizing a larger net
benefit if he or she is given treatment rather than stand-
ard. Such a direct interpretation is not provided by the
acceptability curve. The acceptability curve is the proba-
bility that the average net benefit of a group of patients of
the same size as in the clinical trial will be greater is they
receive treatment rather than standard.
To estimate θ (λ ) we borrow methodology from receiver
operating characteristic curves [10]. An estimate of θ (λ )
is given by:
If there are no ties,  (λ ) is the proportion of all the pos-
sible comparisons of a patient on treatment with a pa-
tient on standard in which the former was observed to
have a larger net benefit. The estimate of the variance of
(λ ), denoted by  , is given by:
The 100(1 - α )% confidence interval, defined as
(λ )±sθ (λ )z1-α /2, can be used to express the uncertainty
regarding (θ ), where Z1-α /2 is the 100(1 - α /2)th per-
centile of the standard normal distribution. We have
made the assumption that in large samples  (λ ) will be
normally distributed.The value λ 0.5, defined at θ  (λ 0.5) =
0.5, provides a non-parametric estimator of the ICER,
since it is that value of λ  for which treatment and stand-
ard are equally cost-effective in the sense that Pr
[bTk(λ 0.5) > bSi(λ 0.5)] = 0.5. The quantities λ L and λ U,
defined as  (λ L)+ sθ (λ L)Z1-α /2 = 0.5 and  (λ U)-
sθ (λ U)Z1-α /2 = 0.5, respectively, are the corresponding
lower and upper non-parametric confidence intervals for
the ICER.
The hypothesis H0: θ  (λ ) = 0.5 versus H1: θ  (λ ) > 0.5 can
be tested at the level α  by rejecting H0 if  .
Rejecting H0 leads to the conclusion that the data pro-
vide evidence that treatment is cost-effective.
Suppose there is an interest in comparing θ  (λ ) between
patient subgroups, say between males and females. To
achieve this, let  M(λ ) and  F(λ ) be the estimator of θ
(λ ) for males and females, respectively, with correspond-
ing estimated variances,   and  . Then the
hypothesis that θ  (λ ) is the same for males and females
can be rejected, at the α -level, 2-sided, if
There is an important distinction to be made between
A(λ ) and  (λ ). As sample size increases, A(λ ) approach-
es 1 if ∆ e λ  - ∆ c > 0, reflecting the certainty that treatment
is cost-effective. If ∆ eλ  - ∆ c ≤  0, A(λ ) approaches 0, re-
flecting the certainty that treatment is not cost-effective.
The quantity  (λ ), being independent of sample size, ap-
proaches θ (λ ) regardless of ∆ eλ  - ∆ c. The certainty with
which θ (λ ) is estimated is reflected in sθ (λ ) which is a de-
creasing function of the sample size.
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Example
In a trial of symptomatic hormone resistant prostate
cancer [11,12], 161 patients were randomized between
prednisone alone (S) and prednisone plus mitoxantrone
(T). Although there was no statistically significant differ-
ence in survival, there was better palliation with T. Cost
data, including hospital admissions, outpatient visits, in-
vestigations, therapies and palliative care, were collected
retrospectively on the 114 patients from the three largest
centres. Survival was quality-adjusted using the EORTC
quality of life questionnaire QLQ-C30. All patients were
followed until death. The sample means and the sample
variance-covariance information can be found in Table 1.
Cost is given in Canadian dollars (CAD$) and effective-
ness in quality-adjusted life-weeks (QALW).
A plot of  (λ ), complete with 90% confidence intervals
can be found in Figure 1. In this example all three plots
have positive slope over the range of λ  shown, although
this would not be true for all examples. For example, by
definition θ  (0) = Pr(cTk - cSj < 0) and θ  (λ ) approaches
Pr(eTk - eSj > 0) as λ  becomes arbitrarily large, for any k
and j. Therefore, any example in which Pr(cTk - cSj< 0) >
Pr(eTk - eSj > 0) will have negative slope for some interval
of positive λ . In the prostate example, since  (λ ) crosses
the 0.5 horizontal at λ  = -50, for any value greater than -
50, the estimate of  (λ ) is greater than 0.5. The value -
50 is a non-parametric estimate of the ICER, since for
that value of λ , treatment and standard are equally cost-
effective, in that the probability that a patient on treat-
ment has the same net benefit as a patient on standard is
0.5. This compares to the parametric estimate of -134.
Since the lower bound crosses the 0.5 horizontal at 334,
for any value greater than 334 the hypothesis θ (λ ) < 0.5
can be rejected at the 5% level of significance. Thus, a
non-parametric upper bound of the ICER is 334. This
compares to 378 using Fieller's theorem [13,14]. For this
example a health policy maker can interpret the results
as follows: for any positive λ , the estimated probability
that treatment is cost-effective is greater than 50%; and
for any λ  greater than 334 per QALW, the probability
that treatment is cost-effective is statistically significant-
ly greater than 50%.
Discussion
As an alternative to the acceptability curve, the quantity
θ (λ ) is proposed as a definition for the probability that
treatment is cost-effective. One advantage is that it is not
sample size dependent, i.e. it is a population parameter.
Another is that it has an appropriate interpretation,
namely, it is the proportion of patients that realize a larg-
er net benefit if given treatment rather than standard.
The acceptability curve does not provide this, although
the language often used regarding it, implies that it does.
The use of θ (λ ) should be helpful to policy makers, since
it does not confuse the magnitude of the benefit with the
certainty of its estimate.
Analysis regarding the quantity θ (λ ) is not proposed as
an alternative to traditional cost-effectiveness analysis
Table 1: Sample sizes and parameter estimates for prostate example
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effectiveness average cost
Standard 53 28.1 29039 16.4 7,872,681 2,876
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for allocating health care resources. When allocating a
fixed amount of resources to one of two new treatments,
the proportion of patients receiving an increase in net
benefit would be maximized by choosing the treatment
with the larger θ (λ ) to ∆ c ratio. However, this would not
maximize net benefit, since the ratio may be larger only
because the between-patient variability in cost and effec-
tiveness is smaller, resulting in a larger θ (λ ).
Non-parametric methods can be used to estimate θ (λ )
and its variance. This provides the appropriate confi-
dence intervals and test of hypothesis. In addition, non-
parametric estimates of the ICER and its confidence in-
tervals can be determined. This is of particular impor-
tance in the presence of highly skewed cost data.
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